{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:10:57Z","timestamp":1789132257809,"version":"build-2803163510"},"reference-count":52,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the 52-week safety\/tolerability of oral olanzapine for adolescents with schizophrenia or bipolar mania and compare effectiveness of a standard versus intense behavioral weight intervention in mitigating risk of weight gain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Patients 13\u201317 years old with schizophrenia (Brief Psychiatric Rating Scale for Children [BPRS-C] total score &gt;30; item score \u22653 for hallucinations, delusions, or peculiar fantasies) or bipolar I disorder (manic or mixed episode; Young Mania Rating Scale [YMRS] total score \u226515) received open-label olanzapine (2.5\u201320\u2009mg\/day) and were randomized to standard (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009102; a single weight counseling session) or intense (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009101; weight counseling at each study visit) weight intervention. The primary outcome measure was mean change in body mass index (BMI) from baseline to 52 weeks using mixed-model repeated measures. Symptomatology was also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      No statistically significant differences between groups were observed in mean baseline-to-52-week change in BMI (standard: +3.6\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; intense: +2.8\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.150) or weight (standard: +12.1\u2009kg; intense: +9.6\u2009kg;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.148). Percentage of patients at endpoint who had gained \u226515% of their baseline weight was 40% for the standard group and 31% for the intense group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.187). Safety\/tolerability results were generally consistent with those of previous olanzapine studies in adolescents, with the most notable exception being the finding of a mean decrease in prolactin. On symptomatology measures, patients with schizophrenia had a mean baseline-to-52-week change in BPRS-C of \u221232.5 (standard deviation [SD]\u2009=\u200910.8), and patients with bipolar disorder had a mean change in YMRS of \u221216.7 (SD\u2009=\u20098.9), with clinically and statistically significant improvement starting at 3\u20134 days for each.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Long-term weight gain was high in both groups, with no statistically significant differences between the standard or intense behavioral weight interventions in BMI or weight. Safety, tolerability, and effectiveness findings were generally consistent with the known profile of olanzapine in adolescents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2016.0010","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T15:27:54Z","timestamp":1474990074000},"page":"922-934","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder"],"prefix":"10.1177","volume":"26","author":[{"given":"Holland C.","family":"Detke","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa P.","family":"DelBello","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Landry","sequence":"additional","affiliation":[{"name":"Eli Lilly Canada","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki Poole","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Heinloth","sequence":"additional","affiliation":[{"name":"inVentiv Health Clinical, LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf W.","family":"Dittmann","sequence":"additional","affiliation":[{"name":"University of Heidelberg","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.042853"},{"key":"e_1_3_3_3_1","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders 4th ed. Text Revision. Washington DC: American Psychiatric Association; 2000."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.463003.x"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0886"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.smj.0000167621.49292.11"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2011.592546"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000220851.94392.30"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-010-0177-z"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbt196"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214530"},{"key":"e_1_3_3_13_1","unstructured":"Eli Lilly and Company: Zyprexa (Olanzapine) [Package Insert]. Indianapolis (Indiana) 2013."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005148.pub2"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2008.0508"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0104"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Guy W: ECDEU Assessment Manual for Psychopharmacology Revised 1976. Rockville MD: National Institute of Mental Health Early Clinical Drug Evaluation Psychopharmacology Research Branch 1976 pp. 217\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.10.1652"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05627gre"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mhpa.2015.04.001"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199707000-00021"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e3181900404"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m03538"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0020"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370104601004"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200103000-00013"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1984.01790130053007"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.02.030"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01046218"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/11204430-000000000-00000"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00797.x"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182962480"},{"key":"e_1_3_3_33_1","first-page":"10","article-title":"The brief psychiatric rating scale for children","volume":"18","author":"Overall JE","year":"1982","unstructured":"Overall JE, , Pfefferbaum B: The brief psychiatric rating scale for children. Psychopharmacol Bull, 18:10\u201316, 1982.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.14423\/SMJ.0000000000000127"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062514"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00906.x"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Posner K: State of the Science: Measurement of Suicidal Adverse Events and the Columbia Suicide Severity Rating Scale. Boca Raton NCDEU 2007.","DOI":"10.1037\/t52667-000"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04994yel"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/00048670701689428"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338548"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.24.2697"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0786"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199506000-00012"},{"key":"e_1_3_3_46_1","first-page":"141","volume-title":"Acute Care Psychiatry Diagnosis and Treatment","author":"Tohen M","year":"1997","unstructured":"Tohen M: Mania. In: Acute Care Psychiatry Diagnosis and Treatment. Edited by Sederer LI, , Rotchschiled AJ. Baltimore, MD: Williams & Wilkins, 1997, pp. 141\u2013165."},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06111932"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01416.x"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/jan.12012"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00498-X"},{"key":"e_1_3_3_51_1","unstructured":"World Health Organization. Growth Reference Data for 5\u201319 years 2007. Available at www.who.int\/growthref\/who2007_bmi_for_age\/en (Last accessed October15 2015)."},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199507000-00010"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2016.0010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2016.0010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2016.0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:42:45Z","timestamp":1779694965000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2016.0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1089\/cap.2016.0010"],"URL":"https:\/\/doi.org\/10.1089\/cap.2016.0010","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}